Company news

aTyr Pharma, Inc. news in 2021

aTyr Pharma, Inc.'s news releases, calls and decks from 2021, newest first.

View company

aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

December 23, 2021

aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923

November 29, 2021

aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

November 9, 2021

aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting

November 8, 2021

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

November 2, 2021

aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs

October 5, 2021

aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting

September 30, 2021

aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 19, 2021

aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock

September 15, 2021

aTyr Pharma Announces Proposed Public Offering of Common Stock

September 14, 2021

aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis

September 12, 2021

aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update

August 9, 2021

aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University

August 9, 2021

aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress

August 8, 2021

aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung

July 28, 2021

aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis

July 7, 2021

aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen

May 24, 2021

aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810

May 18, 2021

aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update

May 12, 2021

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

May 11, 2021

aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research

May 10, 2021

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial Results

May 5, 2021

aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810

April 13, 2021

aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor

April 7, 2021

aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update

March 22, 2021

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial Results

March 15, 2021

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

March 14, 2021

aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

March 10, 2021

aTyr Pharma Announces New tRNA Synthetase Discovery Programs

February 10, 2021

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan

January 13, 2021

aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

January 3, 2021

Decks in 2021